These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

493 related items for PubMed ID: 21868753

  • 21. Safety and efficacy of the simultaneous administration of udenafil and an alpha-blocker in men with erectile dysfunction concomitant with BPH/LUTS.
    Chung BH, Lee JY, Lee SH, Yoo SJ, Lee SW, Oh CY.
    Int J Impot Res; 2009; 21(2):122-8. PubMed ID: 19194451
    [Abstract] [Full Text] [Related]

  • 22. Efficacy and safety of the coadministration of tadalafil once daily with finasteride for 6 months in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia.
    Casabé A, Roehrborn CG, Da Pozzo LF, Zepeda S, Henderson RJ, Sorsaburu S, Henneges C, Wong DG, Viktrup L.
    J Urol; 2014 Mar; 191(3):727-33. PubMed ID: 24096118
    [Abstract] [Full Text] [Related]

  • 23. A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with α-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia.
    Gacci M, Corona G, Salvi M, Vignozzi L, McVary KT, Kaplan SA, Roehrborn CG, Serni S, Mirone V, Carini M, Maggi M.
    Eur Urol; 2012 May; 61(5):994-1003. PubMed ID: 22405510
    [Abstract] [Full Text] [Related]

  • 24. Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study.
    Roehrborn CG, McVary KT, Elion-Mboussa A, Viktrup L.
    J Urol; 2008 Oct; 180(4):1228-34. PubMed ID: 18722631
    [Abstract] [Full Text] [Related]

  • 25. Effectiveness of tadalafil 5 mg once daily in the treatment of men with lower urinary tract symptoms suggestive to benign prostatic hyperplasia with or without erectile dysfunction: results from naturalistic observational TadaLutsEd study.
    Bechara A, Casabe A, Rodriguez Baigorri G, Cobreros C.
    J Sex Med; 2014 Feb; 11(2):498-505. PubMed ID: 24224728
    [Abstract] [Full Text] [Related]

  • 26. Efficacy and safety of tamsulosin hydrochloride compared to doxazosin in the treatment of Indonesian patients with lower urinary tract symptoms due to benign prostatic hyperplasia.
    Rahardjo D, Soebadi DM, Sugandi S, Birowo P, Djati W, Wahyudi I.
    Int J Urol; 2006 Nov; 13(11):1405-9. PubMed ID: 17083392
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Tadalafil: a phosphodiesterase-5 inhibitor for benign prostatic hyperplasia.
    Cantrell MA, Baye J, Vouri SM.
    Pharmacotherapy; 2013 Jun; 33(6):639-49. PubMed ID: 23529917
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Hemodynamic effects of once-daily tadalafil in men with signs and symptoms of benign prostatic hyperplasia on concomitant α1-adrenergic antagonist therapy: results of a multicenter randomized, double-blind, placebo-controlled trial.
    Goldfischer E, Kowalczyk JJ, Clark WR, Brady E, Shane MA, Dgetluck N, Klise SR.
    Urology; 2012 Apr; 79(4):875-82. PubMed ID: 22341603
    [Abstract] [Full Text] [Related]

  • 31. Erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS/BPH) combined responders to tadalafil after 12 weeks of treatment.
    Roehrborn CG, Egan KB, Miner MM, Ni X, Wong DG, Rosen RC.
    BJU Int; 2016 Jul; 118(1):153-60. PubMed ID: 26765325
    [Abstract] [Full Text] [Related]

  • 32. Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia.
    McVary KT, Roehrborn CG, Kaminetsky JC, Auerbach SM, Wachs B, Young JM, Esler A, Sides GD, Denes BS.
    J Urol; 2007 Apr; 177(4):1401-7. PubMed ID: 17382741
    [Abstract] [Full Text] [Related]

  • 33. Tadalafil Improves Symptoms, Erectile Function and Quality of Life in Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (KYU-PRO Study).
    Takahashi R, Miyazato M, Nishii H, Sumino Y, Takayama K, Onzuka M, Oshiro T, Saito S, Fujimoto N, Mimata H, Eto M.
    Low Urin Tract Symptoms; 2018 Jan; 10(1):76-83. PubMed ID: 29341501
    [Abstract] [Full Text] [Related]

  • 34. Efficacy and safety of combined therapy with terazosin and tolteradine for patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: a prospective study.
    Yang Y, Zhao XF, Li HZ, Wang W, Zhang Y, Xiao H, Zhang X.
    Chin Med J (Engl); 2007 Mar 05; 120(5):370-4. PubMed ID: 17376305
    [Abstract] [Full Text] [Related]

  • 35. Effects of three types of alpha-1 adrenoceptor blocker on lower urinary tract symptoms and sexual function in males with benign prostatic hyperplasia.
    Yokoyama T, Hara R, Fukumoto K, Fujii T, Jo Y, Miyaji Y, Nagai A, Sone A.
    Int J Urol; 2011 Mar 05; 18(3):225-30. PubMed ID: 21272091
    [Abstract] [Full Text] [Related]

  • 36. Tadalafil versus solifenacin for persistent storage symptoms after prostate surgery in patients with erectile dysfunction: a prospective randomized study.
    Maselli G, Bergamasco L, Silvestri V, Gualà L, Pace G, Vicentini C.
    Int J Urol; 2011 Jul 05; 18(7):515-20. PubMed ID: 21592232
    [Abstract] [Full Text] [Related]

  • 37. Alfuzosin 10 mg once daily for treating benign prostatic hyperplasia: a 3-year experience in real-life practice.
    Vallancien G, Emberton M, Alcaraz A, Matzkin H, van Moorselaar RJ, Hartung R, Harving N, Elhilali M, ALF-ONE Study Group.
    BJU Int; 2008 Apr 05; 101(7):847-52. PubMed ID: 18321317
    [Abstract] [Full Text] [Related]

  • 38. Comparison of the efficacy and safety of 5-mg once-daily versus 5-mg alternate-day tadalafil in men with erectile dysfunction and lower urinary tract symptoms.
    Choi H, Kim JH, Shim JS, Park JY, Kang SH, Moon DG, Cheon J, Lee JG, Kim JJ, Bae JH.
    Int J Impot Res; 2015 Apr 05; 27(1):33-7. PubMed ID: 24990200
    [Abstract] [Full Text] [Related]

  • 39. Treatment satisfaction with tadalafil or tamsulosin vs placebo in men with lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH): results from a randomised, placebo-controlled study.
    Oelke M, Giuliano F, Baygani SK, Melby T, Sontag A.
    BJU Int; 2014 Oct 05; 114(4):568-75. PubMed ID: 24612148
    [Abstract] [Full Text] [Related]

  • 40. Urodynamic effects of once daily tadalafil in men with lower urinary tract symptoms secondary to clinical benign prostatic hyperplasia: a randomized, placebo controlled 12-week clinical trial.
    Dmochowski R, Roehrborn C, Klise S, Xu L, Kaminetsky J, Kraus S.
    J Urol; 2013 Jan 05; 189(1 Suppl):S135-40. PubMed ID: 23234619
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 25.